Description
BPC-157 & TB-500 Blend 20mg – Research Peptide Blend
BPC-157 & TB-500 Blend 20mg is a research-grade peptide formulation supplied for controlled laboratory investigation involving peptide signaling, extracellular matrix biology, and cellular pathway analysis.
This formulation contains two peptides frequently referenced in scientific literature:
• BPC-157 – 10mg
• TB-500 (Thymosin Beta-4) – 10mg
Both peptides have appeared in experimental research examining molecular pathways related to connective tissue biology, cellular signaling systems, and peptide-mediated biochemical processes.
The combined format allows researchers to investigate these peptides within controlled laboratory models examining peptide interactions and signaling pathways.
BPC-157 & TB-500 Blend 20mg is supplied strictly for in-vitro laboratory research and analytical investigation. This compound is not approved for human or veterinary use.
What Is BPC-157 & TB-500 Blend?
This research formulation combines two peptides commonly referenced in experimental literature.
BPC-157 (10mg)
BPC-157 is a synthetic peptide fragment derived from a protein sequence associated with gastric peptides.
Scientific literature referencing BPC-157 has examined experimental models involving:
• Peptide signaling within connective tissue research models
• Nitric oxide–related molecular pathways
• Vascular signalling systems
• Cellular pathway analysis related to extracellular matrix biology
These topics remain areas of ongoing laboratory investigation.
TB-500 (Thymosin Beta-4) – 10mg
TB-500 is a synthetic peptide related to Thymosin Beta-4, a naturally occurring peptide present in multiple tissue types.
Research literature referencing Thymosin Beta-4–related peptides has examined laboratory models involving:
• Actin regulation within cellular systems
• Cellular migration signaling pathways
• Vascular signalling pathways
• Peptide activity within musculoskeletal research models
These areas continue to be subjects of experimental investigation.
Areas of Scientific Investigation
Research literature referencing BPC-157 and TB-500 has examined laboratory models involving:
• Peptide signaling pathways within connective tissue research
• Vascular signalling pathway analysis
• Cellular signaling systems related to extracellular matrix biology
• Peptide-receptor interaction studies
• Musculoskeletal cellular research models
These references are provided for informational context regarding the compounds’ presence in scientific research.
Laboratory Research Contexts
Researchers may investigate the BPC-157 & TB-500 Blend within experimental frameworks such as:
• Peptide interaction studies
• Molecular signaling pathway analysis
• Extracellular matrix and connective tissue research models
• Cellular peptide signaling investigations
• Peptide structure and stability studies
BPC-157 & TB-500 Blend 20mg – Research Supply Specifications
• Multi-peptide research formulation
• Total peptide content: 20mg lyophilized powder
• Composition: 10mg BPC-157 + 10mg TB-500
• Analytical purity standard: 99%+
• Third-party laboratory testing for identity and purity
• Manufactured under controlled quality standards
• Canada-based fulfillment
• Batch-level quality verification
Purity & Quality Assurance
ExoLabz provides research peptides manufactured to high analytical standards. ExoLabz products undergo independent third-party testing to verify peptide identity and purity. Results are published on this site.
Researchers may conduct additional analytical verification if required for laboratory use. If validated testing confirms a verified purity discrepancy, ExoLabz provides refund and testing reimbursement in accordance with company policy.
Important Legal Notice
For Research Purposes Only
BPC-157 & TB-500 Blend 20mg is supplied strictly for laboratory research and analytical use.
This compound is not intended for human consumption, veterinary use, clinical research involving human subjects, therapeutic use, or diagnostic applications.
This product has not been evaluated or approved by Health Canada, the U.S. Food and Drug Administration (FDA), or any other regulatory authority.
By purchasing this product, the buyer confirms that the material will be handled only by qualified professionals and used solely for lawful laboratory research purposes.
Compound identity and specification
BPC-157 & TB-500 BLEND 20mg is a blend, so identity is given per component. Each formula, mass and registry number below is verified against PubChem and can be looked up directly.
| Component | Sequence | Formula | Mass (g/mol) | CAS |
|---|---|---|---|---|
| BPC-157 CID 9941957 | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV) | C62H98N16O22 | 1419.5 | 137525-51-0 |
| TB-500 CID 62707662 | Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (acetylated LKKTETQ, the thymosin beta-4 17-23 region) | C38H68N10O14 | 889.0 | 885340-08-9 |
| Total peptide content | 20 mg total — BPC-157 10 mg and TB-500 10 mg |
|---|---|
| Physical form | Lyophilised powder in a sealed vial |
| Analysis | Third-party HPLC; the result for this product is published on this page |
| Supplied for | Laboratory research use only |
Analytical note — BPC-157. A pentadecapeptide with three consecutive prolines. Proline-rich sequences broaden on reverse-phase HPLC because the bond preceding each proline interconverts between cis and trans conformations slowly relative to the run, so a broad or shouldered peak is a property of the molecule rather than evidence of a second substance.
Analytical note — TB-500. TB-500 is the short acetylated fragment, not full-length thymosin beta-4, which is a 43-residue protein of about 4,963 g/mol. The two are routinely conflated. A mass near 889 confirms the fragment; a mass near 4,963 would be a different product entirely.
Identity references The molecular formula, molecular mass and CAS registry number above are taken from the PubChem record linked in the table, not from a supplier datasheet, so every figure can be checked against an independent source in one click. Sequences are given as reported in the peptide literature, in the one-letter or three-letter convention as appropriate, with any non-standard residue named in full. Where a compound exists in more than one form — a free peptide and a metal complex, a fragment and its parent protein, a modified and an unmodified analog — the form supplied is the one identified here, and the mass on the certificate of analysis is what distinguishes it.
Research Literature
Peer-reviewed studies involving this compound and its class. All findings listed are from in vitro, cell culture or animal models and are provided for scientific reference only. This product is supplied for laboratory research and is not approved for human consumption, clinical, or veterinary use.
- Chang CH, et al. J Appl Physiol. 2011;110(3):774-780. In rat Achilles tendon explant culture and isolated tendon fibroblasts, measured explant outgrowth, fibroblast survival under oxidative stress, migration, and FAK/paxillin phosphorylation. Source · PMID 21030672
- Hsieh MJ, et al. J Mol Med (Berl). 2017;95(3):323-333. In chick chorioallantoic membrane assay, a rat hind-limb ischaemia model and human endothelial cell culture, measured vessel density, endothelial tube formation and VEGFR2-Akt-eNOS phosphorylation. Source · PMID 27847966
- Chang CH, et al. Molecules. 2014;19(11):19066-19077. In primary tendon fibroblasts from Sprague-Dawley rat Achilles tendon, measured growth hormone receptor mRNA and protein levels, PCNA expression and JAK2 phosphorylation. Source · PMID 25415472
- Bock-Marquette I, et al. Nature. 2004;432(7016):466-472. In embryonic mouse cardiomyocyte and endothelial culture and a mouse coronary artery ligation model, measured cell migration, myocyte survival and ILK/Akt kinase activity. Source · PMID 15565145
- Malinda KM, et al. FASEB J. 1997;11(6):474-481. In human umbilical vein endothelial cell (HUVEC) culture, measured directional chemotactic migration in Boyden-chamber assays. Source · PMID 9194528
- Philp D, et al. FASEB J. 2003;17(14):2103-2105. In HUVEC culture and chick aortic arch explants, measured migration, adhesion and vessel sprouting elicited by the LKKTETQ actin-binding motif at approximately 50 nM. Source · PMID 14500546
Literature notes: The published base for this compound is small and concentrated in a limited number of research groups, with little independent replication of in vivo findings. Published work concerns full-length thymosin beta-4 or its LKKTETQ actin-binding fragment. Equivalence between those and material marketed as TB-500 is not established in the literature.
Related Research Compounds
Browse more compounds in BPC-157 & TB-500 Peptides, or view the full research peptide catalogue.
